Friday 17 August 2018

From Merck’s CCK- Antagonists Via 4-Amino-2(5H)- Furanones towards 5-Hydroxy-Pyrrol-2-Ones: Design, Synthesis and Evaluation of PNB-001 & PNB-081 as Experimental Therapeutic Agents in Pain Management: (DDIPIJ) - Lupine Publishers


From Merck’s CCK- Antagonists Via 4-Amino-2(5H)- Furanones towards 5-Hydroxy-Pyrrol-2-Ones: Design, Synthesis and Evaluation of PNB-001 & PNB-081 as Experimental Therapeutic Agents in Pain Management by Eric Lattmann, JintanaSattayasai, Ramesh Narayanan in Drug Designing & Intellectual Properties International Journal (DDIPIJ) in Lupine Publishers

Arylated 5-hydroxy-pyrrol-2-ones were prepared in 2 synthetic steps from muco-chloric acid and were optimised as CCK / CCK2 selective ligands using radio labelled binding assays. A potent CCK selective ligand was identified (PNB-081: CCK1=20nM) as well as a potent CCK2 ligand (PNB-001, IC50= 22nM) during a systematic SAR optimisation. The antagonism was confirmed for both ligands by using isolated tissue preparations with CCK5 and CCK8S. Subsequent in vivo evaluation revealed analgesic activity for the gastrin CCK2 antagonist PNB-001, in the hotplate and tail immersion test at 0.5mg /kg by IP administration in mice. The cholecystokinin antagonist PNB-081 potentiated the analgesic effect of morphine and reversed opiate tolerance in mice from doses >1 mg/kg by oral administration.

http://www.lupinepublishers.com/ddipij/abstracts/DDIPIJ.MS.ID.000105.php  
http://www.lupinepublishers.com/ddipij/fulltext/DDIPIJ.MS.ID.000105.php
http://www.lupinepublishers.com/ddipij/pdf/DDIPIJ.MS.ID.000105.pdf

No comments:

Post a Comment

Note: only a member of this blog may post a comment.